These compounds exhibit efficacy across a spectrum of solid tumors and hematological neoplasms, offering hope for patients with MYC-driven cancers, metastatic neuroblastoma, glioblastoma multiforme, and various others [38,39,41,42]. This evidence concerns the gene MYC and glioblastoma.